PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?

Jacob J Adashek¹, Pedro N Aguiar^{2

3}, Pedro Castelo-Branco^{4

5}, Gilberto L Lopes Jr⁶, Ramon Andrade de Mello^{7

8

9}

Affiliations

¹ Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, Pomona, CA, USA.
² Faculdade de Medicina do ABC, Santo André, Brazil.
³ Américas Centro de Oncologia Integrado, São Paulo, Brazil.
⁴ Department of Biomedical Sciences & Medicine, Division of Oncology, University of Algarve, 8005-139, Faro, Portugal.
⁵ Algarve Biomedical Center, Campus Gambelas, Edificio 2, 8005-139, Faro, Portugal.
⁶ Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA.
⁷ Department of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
⁸ Division of Medical Oncology, Hospital 9 de Julho, São Paulo, Brazil.
⁹ Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, Faro, Portugal.

Jacob J Adashek et al. Future Oncol. 2019 May.

. 2019 May;15(13):1407-1410.

doi: 10.2217/fon-2019-0044. Epub 2019 May 8.

Jacob J Adashek¹, Pedro N Aguiar^{2

3}, Pedro Castelo-Branco^{4

5}, Gilberto L Lopes Jr⁶, Ramon Andrade de Mello^{7

8

9}

¹ Western University of Health Sciences, College of Osteopathic Medicine of the Pacific, Pomona, CA, USA.
² Faculdade de Medicina do ABC, Santo André, Brazil.
³ Américas Centro de Oncologia Integrado, São Paulo, Brazil.
⁴ Department of Biomedical Sciences & Medicine, Division of Oncology, University of Algarve, 8005-139, Faro, Portugal.
⁵ Algarve Biomedical Center, Campus Gambelas, Edificio 2, 8005-139, Faro, Portugal.
⁶ Sylvester Comprehensive Cancer Center at the University of Miami, Miami, FL, USA.
⁷ Department of Medical Oncology, Federal University of São Paulo, São Paulo, Brazil.
⁸ Division of Medical Oncology, Hospital 9 de Julho, São Paulo, Brazil.
⁹ Departamento de Ciências Biomédicas e Medicina, Universidade do Algarve, Faro, Portugal.

No abstract available

Keywords: CDK inhibitors; Phase III; hormone-positive HER-2-negative advanced breast cancer; overall survival.

Publication types